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May Supplement 20094S Plenary SessionsConclusion: Parenchymal loss occurs in 31% of patients and is associ-
ated with markers of impaired parenchymal perfusion (RI and GSG) at the
time of intervention. Pre-existing renal size or volumes were not predictive
of parenchymal loss. Parenchymal loss is associated with a significant de-
crease in survival and a marked increased renal related morbidity and
progression to hemodialysis. Monitoring parenchymal loss will identify
high-risk patients after renal intervention.
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SS9.
Successful Management of Acute Complicated Type B Dissections with
TEVAR and Adjunctive Endovascular Techniques: Malperfusion Ver-
sus Rupture
Elena Y. Rakhlin, Wilson Y. Szeto, Ronald M. Fairman, Benjamin M.
Jackson, G. William Moser, Edward Y. Woo. Hospital of University of
Pennsylvania, Philadelphia, PA
Objective: Complicated acute type B aortic dissections require urgent
intervention. Our group has previously reported successful treatment of this
condition with TEVAR. We report our continued experience, and contrast
the technical aspects and outcomes of malperfusion vs. rupture.
Methods: From 2004-2008, 43 patients (60 13 years; 28 men) with
an acute complicated type B dissection underwent TEVAR. Indications for
treatment were malperfusion - 26 (60%) and rupture - 22 (51%); 5 (11%)
presented with both. Renal malperfusion was present in 17 (65%), visceral -
17 (65%), lower extremity - 14 (54%). Patients were followed 1 to 49
months (16  12).
Results: Excellent technical and clinical results were achieved in both
groups. Onset of intervention was significantly earlier in patients with
rupture (0.6 vs. 1.9 days, p0.02). Endograft utilization and deployment
were comparable, including device number (2.1; 2.2; p0.94), left SCA
coverage (17; 16; p0.58), and celiac coverage (0; 0). One-year survival was
greater than 94% in both groups. While length of stay was longer with
malperfusion, neither presentation conferred an inferior outcome (Table).
Although TEVAR alone effectively treated aortic rupture in 21 patients
(95%), malperfusion was rectified in only 15 (58%) cases. Eleven patients
(42%) required adjunctive procedures to restore end-organ perfusion: 50%
-lower extremity, 18% - renal, 12% - visceral. No patient suffered limb loss or
bowel resection; renal function recovered in 94% of patients with malperfu-
sion.
Conclusions: Malperfusion and rupture complicating acute type B
aortic dissection are both successfully managed with TEVAR. However, the
endovascular strategy must be customized to each presentation to achieve
these results. While TEVAR alone is sufficient to address the aortic disrup-
tion in patients with rupture, adjunctive procedures are often necessary in
malperfusion cases.
Malperfusion Rupture P value
ICU stay (days) 5.1  0.8 6.4  0.8 0.98
LOS (days) 19.6  2.5 13.2  1.2 0.04
Blood products
(patients)
15/26 9/22 0.59
Stroke (patients) 0/26 1/22 0.93
Spinal ischemia
(patients)
2/26 1/22 0.65
30-day mortality
(patients)
0/26 1/22 0.93
1-year survival
(patients)
21/22 16/17 0.85
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SS10.
Temporary IVC Filters Usually Become Permanent Except When
Placed in Trauma Patients for Prophylactic Indications
Peter B Brant-Zawadzki, Faheem Akhtar, Michelle T Mueller, Daniel V
Kinikini, Larry W Kraiss, Mark R Sarfati. University of Utah, Salt Lake City,
UTObjective(s): The optimal use of retrievable IVC filters remains un-
clear. We compared our recent 5-year experience with retrievable filters
placed for prophylactic or therapeutic indications.
Methods: A retrospective, single institution chart review was per-
formed to identify patients who had a retrievable filter placed between July
2002 and December 2007. Patient data included age, sex, admitting diag-
nosis, indication for filter, dates of insertion, retrieval/attempted retrieval
and reasons for unsuccessful retrieval. Comparisons were made by Chi-
square testing.
Results: During the study period, 462 retrievable filters were placed
in patients who had a confirmed diagnosis of VTE (or were considered
high risk for VTE) who also had an absolute or relative contraindication
to anticoagulation. Overall, a retrieval attempt was made in 201 (44%)
patients and was successful in 174 (87% of attempts but only 38% of all
filters placed) [See table]. Retrieval was much more likely to be attempted
in patients who received filters for prophylactic (64%) v therapeutic (28%)
indications (p 0.0001). Lack of an attempt to retrieve the filter was due
to loss of follow-up (n  141; no difference between prophylactic or
therapeutic groups), contraindication to anticoagulation (n  75), or
patient death (n  46). Retrieval failure (n  27) was due to: filter
ingrowth (n 11), retained thrombus (n 10), or tilt (n 6). Duration
of implantation 30 days was strongly and inversely correlated with
retrieval success [30 day retrieval rate  92% (131/142), 30 day
retrieval rate  73% (43/59); p  0.0002].
Conclusions: The only group with a 50% retrieval rate were trauma
patients who received prophylactic filters. All other patient groups were
more likely to have their filters left in permanently. If attempted, retrieval
rates were relatively high regardless of indication or underlying diagnosis
although duration of implantation was a significant factor in unsuccessful
filter retrieval.
Comparison between Prophylactic & Therapeutic Filters
Prophylactic
(no confirmed VTE)
Therapeutic
(confirmed VTE)
N [Total  462] (%) 194 (42) 268 (58)
Attempted Retrieval (%) 125 (64) 76 (28)
Successful Retrieval
(% of attempts)
111 (89) 63 (84)
Retrieval Rate (%) by
Diagnosis
Trauma (n  114/188,
61%)
98/150 (65) 16/38 (42)
Cancer (n  10/85, 12%) 1/10 (10) 9/75 (12)
Neuro (n  6/34, 18%) 3/8 (38) 3/26 (12)
Ortho (n  11/32, 34%) 4/13 (31) 7/19 (37)
Other Med/Surg
(n  33/123, 27%)
5/13 (38) 28/110 (25)
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SS11.
Aggressive Lipid-Lowering is More Effective Than Moderate Lipid-
Lowering Treatment in Carotid Plaque Stabilization
Nikolaos P EKadoglou1, Nikolaos Sailer1, AnestisMoumtzouoglou1, Alkis-
tis Kapelouzou2, Grigorios Fotiadis1, Ioulia Vitta1, Ioannis Kakisis3, Ef-
thimios Avgerinos3, Thomas Gerasimidis1, Panayotis Karayannacos2, Chris-
tos D Liapis1. 1Aristotle’s University of Thessaloniki, Thessaloniki, Greece;
2Foundation of Biomedical Research, Academy of Athens, Athens, Greece;
3University of Athens, Athens, Greece
Objective: Atherosclerotic plaque stabilization is a promising strategy
to prevent cerebrovascular events in patients with moderate carotid stenosis.
This prospective study examined whether intensive lipid-lowering therapy is
more effective in increasing carotid plaque echogenicity, assessed by Gray-
Scale Median (GSM) score, and suppressing serum levels of osteopontin
(OPN) and osteoprotegerin (OPG) in patients with carotid stenosis.
Methods: 120 patients (51M/69F), aged 55-75, with carotid stenosis
(NASCET: 40-60% for symptomatic and 40-70% for asymptomatic pa-
tients), thus without indications for surgical intervention, were included.
Patients with previous use of statins were excluded. Patients were random-
ized to either intensive lipid-lowering therapy (Group A; n60: target
LDL-C70mg/dl) or moderate lipid-lowering therapy (Group B; n60:
target LDL-C100mg/dl). The ratio symptomatic/asymptomatic patients
